| Tested in both acute leukemia and CML models |
| Graft type: blood stem cells versus bone marrow |
| Age at transplantation: <40 y versus ≥40 y |
| Sex: male versus female |
| Karnofsky performance status: <90% versus 90%-100% |
| Disease stage at transplantation: second CR, second CP or AP versus first CR or CP |
| White blood cell count at diagnosis: high versus low* |
| Conditioning regimen: TBI versus non-TBI |
| GVHD prophylaxis: CsA ± other versus CsA + MTX ± other versus other |
| Growth factors given in first 7 d after transplantation: yes versus no |
| Tested in acute leukemia models only |
| Disease type: AML versus ALL |
| FAB classification: FAB M4 M5 versus other AML versus T-cell ALL versus other ALL |
| Tested in CML models only |
| Interval from diagnosis to transplantation: ≥1 y versus <1 y |
| Tested in both acute leukemia and CML models |
| Graft type: blood stem cells versus bone marrow |
| Age at transplantation: <40 y versus ≥40 y |
| Sex: male versus female |
| Karnofsky performance status: <90% versus 90%-100% |
| Disease stage at transplantation: second CR, second CP or AP versus first CR or CP |
| White blood cell count at diagnosis: high versus low* |
| Conditioning regimen: TBI versus non-TBI |
| GVHD prophylaxis: CsA ± other versus CsA + MTX ± other versus other |
| Growth factors given in first 7 d after transplantation: yes versus no |
| Tested in acute leukemia models only |
| Disease type: AML versus ALL |
| FAB classification: FAB M4 M5 versus other AML versus T-cell ALL versus other ALL |
| Tested in CML models only |
| Interval from diagnosis to transplantation: ≥1 y versus <1 y |
CML denotes chronic myelogenous leukemia; CR, complete remission; CP, chronic phase; AP, accelerated phase; TBI, total-body irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; and FAB, French-American-British.
High was above 75 × 109/L white blood cells for patients with acute leukemia and above 200 × 109/L white blood cells for patients with CML.